Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs iShares China Large-Cap ETF (FXI) Price & Performance

Boston Scientific CorporationTrade
iShares China Large-Cap ETFTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs iShares China Large-Cap ETF — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while iShares China Large-Cap ETF trades at $35.35. The key difference: iShares China Large-Cap ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

BSXFXI
Market Cap
$71.46B
Sector
Health
52-Week High
$108.14$41.75
52-Week Low
$42.63$31.59
Enterprise Value
$83.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

iShares China Large-Cap ETF

FXI, the iShares China Large-Cap ETF, trades at $36.17, up 0.61% on the day, with a bullish technical signal driven by moving averages. The ETF benefits from China's strong export data and state-backed economic support, though key financial ratios are not disclosed in the provided data. Recent news highlights China's AI and manufacturing strength as positive catalysts.

Outlook is cautiously optimistic given bullish technicals and macroeconomic tailwinds, but risks include U.S.-China tensions and reliance on financials-heavy exposure. The dividend announcement for 2026 provides income appeal, yet investors face volatility from geopolitical and regulatory uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI